Vaccines have a significant impact on public health, and vaccinology in the era of genomics is taking advantage of new technologies to tackle diseases for which vaccine development has so far been unsuccessful. Almost all existing vaccines were developed based on traditional vaccinology methods, which relied on empirical screening of a few candidates at a time based on known features of the pathogen. However, the ability to sequence a pathogen's genome provides access to its entire antigenic repertoire. As such, genomics has catalysed a shift in vaccine development towards sequence-based 'Reverse Vaccinology' approaches, which use high-throughput in silico screening of the entire genome of a pathogen to identify genes that encode proteins with the attributes of good vaccine targets.
Introduction
Vaccination is one of the most successful and cost-effective ways of improving public health and has been used to save lives for at least two centuries Traditional vaccine development was largely based on Pasteur's principles, which are to "isolate, inactivate, and inject" the disease-causing agent thus producing vaccines composed of inactivated, live attenuated or purified subunits of a microorganism (1) The original idea behind Reverse Vaccinology was to start in silico to screen the entire genome of a pathogen to identify genes that encode proteins with the attributes of good vaccine targets, for example, proteins that are predicted to be surface exposed and that are well conserved between strains. These selected proteins are then expressed in Escherichia coli and used to immunise mice to enable evaluation of immunogenicity and protection based on analysis of antisera by flow cytometry, and in serum bactericidal activity (SBA) and opsonophagocytosis assays or in animal models of infection. Over the past decade, the methodologies used in Reverse Vaccinology projects have greatly progressed beyond the original analysis of a single meningococcal genome (3) . Improved sequencing technologies have greatly increased the number of genomes available and Reverse Vaccinology has evolved to include analysis of several genomes within a species (e.g. pan-genomic analysis of Group B Streptococcus (GBS)) (4), between closely related species (e.g. comparative-genomic analysis of GBS, Group A Streptococcus (GAS) and Streptococcus pneumoniae) or between pathogenic and commensal members of the same species (e.g. comparative/subtractive-genomic of E. coli) (5, 6) . Furthermore, high throughput proteomic analyses are now possible, as proteins and peptides can be easily identified using data obtained by mass spectrometry to search genome databases, and can provide important information for vaccine development (e.g. analysis of the GAS surface proteome) (7, 8) . Protein microarrays can also be used to identify proteins expressed during host infection (9) . As other 4 innovative fields of research have emerged, such as immunoproteomics, structural biology, and systems biology, they have also been applied to vaccine development, and are helping researchers to overcome the limits of conventional approaches in the discovery and development of novel vaccines, especially against infectious diseases caused by diverse and variable microorganisms (10) (11) (12) .
In this review, we summarise the progress of over a decade of genome and proteome-based vaccinology, focusing on several projects that have used Reverse Vaccinology as the main approach for antigen discovery (see Fig. 2 ), including vaccines against N. meningitidis serogroup B, for which an application has been submitted for licensure in Europe, and vaccines against GBS, GAS, S. pneumoniae and E. coli which are being analysed in preclinical studies.
Serogroup B Neisseria meningitidis -classic one-genome Reverse Vaccinology
The development of a serogroup B Neisseria meningitidis (MenB) vaccine represents the first example of the successful application of Reverse Vaccinology (3, (13) (14) (15) . N. meningitidis is a major cause of septicaemia and meningitis leading to high mortality and morbidity worldwide, and MenB is the predominant serogroup responsible for meningococcal disease in most of the developed world Craig Venter Institute (formerly TIGR) USA, Novartis Vaccines and Diagnostics (formerly Chiron Corporation) Italy, and Oxford University UK (18) . With the unravelling of the genome code of this pathogen, researchers were able to select nearly 600 potential vaccine candidates by in silico analysis.
Following this, 350 recombinant proteins were successfully expressed in E. coli and used to immunise mice, from which 91 novel proteins were confirmed to be surface exposed by flow cytometry analysis, and 28 proteins were found to induce bactericidal antibodies (3) . After further analysis, a final 4-component MenB (4CMenB) vaccine was formulated, which consists of 3 recombinant protein antigens (NHBA-GNA1030 and GNA2091-fHbp fusion proteins and NadA) and outer membrane vesicles (OMV) from the strain used for the New Zealand OMV vaccine (contains PorA 1.4) (13).
Using the meningococcal genome, novel vaccine candidates were discovered that have since been identified as important virulence factors. Factor H binding protein (fHbp) binds factor H (fH), a key inhibitor of the complement alternative pathway, and enables the meningococcus to evade killing by 5 the innate immune system (19, 20) . Neisserial heparin binding antigen (NHBA) also plays a role in serum resistance (21) , and the Neisserial adhesin A (NadA) is important for bacterial-host cell interactions (22, 23) .
Molecular epidemiological investigation revealed that the main antigens fHbp, NHBA and NadA, can be classified into 3, 14 and 5 variant groups, respectively (24) . Furthermore, this analysis revealed that prediction of vaccine coverage was not possible on the basis of traditional meningococcal typing systems (24) , such as multi-locus sequence typing (MLST) or capsule-based serogrouping (16, 25) . In the serum bactericidal activity (SBA) assay, which is the correlate of protection used for meningococcal vaccines (26), cross-reactivity exists between NHBA variants (21, 27 ) and the 3 main NadA variants identified in hypervirulent strains (28), however little cross protection is seen between fHbp variant 1 (present in the 4CMenB vaccine) and the other two fHbp variant groups (29, 30).
Furthermore, the level of expression of these antigens varies between strains (21, 29, 31). At this point, it became apparent that a new typing system was needed to predict the potential strain coverage of the 4CMenB vaccine, and the meningococcal antigen typing system (MATS) was developed. MATS is a vaccine antigen-specific sandwich ELISA that measures the amount of each antigen expressed by a strain and its immunologic cross-reactivity with the antigen present in the 4CMenB vaccine (32).
MATS is correlated with killing of strains in the SBA assay, and MATS analysis of large strain panels from many countries predicted that adults and infants immunized with the 4CMenB vaccine would be protected from disease caused by 86% and 77% of the global MenB strains, respectively (32-34).
Clinical trial data from studies with more than 1,800 infants showed that 4CMenB (commercial name Bexsero) is safe and induces a robust immune response. Protective immune responses (human SBA titres ≥1:5) were seen against reference MenB strains containing the vaccine-antigens; at least 99% of participants produced antibodies that killed strains 44/76 (specific for fHbp) and 5/99 (specific for NadA), and 87% produced antibodies that killed strain NZ98/254 (specific for OMV PorA). MATS data together with a comprehensive clinical program with 4CMenB has served as the basis for submission for regulatory approval to the European Medicines Agency (14, 15, (35) (36) (37) (38) (39) .
Streptococcus agalactiae -Pan-genome Reverse Vaccinology
Multigenome Reverse Vaccinology was applied to the Gram-positive pathogen Streptococcus agalactiae (group B streptococcus (GBS)), based on analysis of 8 GBS genomes to address the sequence diversity of this species (4, 40) . GBS transmission mostly occurs from mother to newborn during delivery, causing sepsis, pneumonia and meningitis in the first month of life. GBS also causes severe invasive infections in the elderly, in pregnant women, and patients with underlying diseases 6 (reviewed in 41). There are 9 GBS serotypes, distinguished by their capsular polysaccharide (CPS), and serotypes Ia, Ib, II, III, and V account for the majority of disease in the USA (42) . The risk of neonatal infection is inversely proportional to the maternal amounts of specific antibodies to CPS (43, 44) and CPS-conjugate vaccines are safe and immunogenic in clinical trials (45, 46) . However, there are a number of non-typeable GBS isolates that would not be protected by these vaccines (46, 47) , and efforts to develop vaccines based on conserved protein antigens are in progress (41).
Due to the high level of diversity between GBS strains, Reverse Vaccinology was applied to several genomes to enable the total gene repertoire or 'pan-genome' of the species to be screened for vaccine candidates. Analysis of 8 GBS genomes revealed a core-genome of approximately 1806 genes present in all strains, plus a dispensable-genome of 907 genes that are absent in one or more strains (40) . In silico screening identified 589 predicted surface-exposed proteins, of which 396 were core genes and 193 were dispensable genes (4). Of these, 312 were successfully expressed in E. coli and evaluated for their ability to mediate protection in a mouse maternal immunization-neonatal pup challenge model. Four proteins were found to be protective: GBS322 from the core genome, as well as GBS67, GBS80 and GBS104, which are present in the dispensable genome and would not have been identified if only a single genome had been screened, however, in combination they proved to be protective against a large panel of strains (4).
Interestingly, three of the newly identified protective GBS antigens were seen to assemble into pili, which are long filamentous structures that extend from the bacterial surface and play an important role in virulence of many pathogens (48) . Sequence analysis of a large panel of GBS isolates revealed the presence of 3 pilus islands, PI-1, PI-2a and PI-2b, and all strains characterized to date have at least 1, but often 2, of the islands (48) (49) (50) . Each island encodes a pilus composed of three structural proteins containing a LPXTG motif, the backbone protein (BP) and two ancillary proteins (AP1 and AP2), of which BP and AP1 induce protective antibodies (4, 49, 50) . Moreover, DNA sequence analysis has shown that the three subunits in strains carrying the same island are highly conserved and crossprotective, with the exception of BP-2a that has 6 non cross-protective variants (50) . Based on these data, a vaccine containing 1 component of each pilus (BP-1, BP-2b and AP-2a) was tested and shown to elicit opsonophagocytic antibodies in an in vitro opsonophagocytosis assay and provide a high level of protection against a large panel of virulent strains from key serotypes in the maternal immunization/neonatal pup challenge model (50) .
Streptococcus pyogenes -Comparative genomics and proteomic based Reverse Vaccinology
Streptococcus pyogenes (Group A Streptococcus, GAS) is a Gram-positive pathogen that causes 7 disease ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Despite significant attempts, there is currently no vaccine available against GAS (51, 52) .
Using comparative genomics and bioinformatics, five GAS genomes were analysed for typical pilus regions, which were identified by the presence of genes encoding proteins containing the cellwall-attachment motif LPXTG that were also closely linked with sortase enzymes. Three to five genes coding for LPXTG-containing proteins were identified in the various genomes and a combination of 3 recombinant pilus proteins (Cpa, M1_128 and M1_130) was shown to confer protection in mice against mucosal challenge with virulent GAS strains (53) . GAS pili are encoded by nine different gene clusters and are highly variable, however it was predicted that a vaccine combining 12 backbone variants could provide protection against over 90% of circulating GAS strains (54).
An innovative proteomic-based approach has also been applied to GAS to specifically isolate and identify surface proteins, termed the bacterial surface proteome or 'surfome'. Proteolytic enzymes were used to "shave" the bacterial surface, and the peptides released were analysed by mass spectrometry and identified using the available GAS genome sequences (8). 72 surface-exposed proteins were identified in strain M1_SF370, the majority of which were predicated by PSORT to be surface-associated and which included most of the protective GAS antigens described to date.
Additional analysis of the highly virulent strain M23_DSM2071, led to the identification of 17 surfaceexposed proteins, 14 of which were expressed in E. coli and tested to determine their ability to mediate protection in a mouse model. This approach led to the identification of one new protective antigen (Spy0416), which is highly conserved and a major cell surface component of >70% of the GAS strains (8) .
Streptococcus pneumoniae -Comparative genomics and Reverse Vaccinology
Several classical and genome-based approaches have been applied to Streptococcus pneumoniae for identification of virulence factors and vaccines antigens (55) (56) (57) . S. pneumoniae is a Gram-positive bacterium that causes significant human disease, including sepsis, meningitis, pneumonia, otitis media and sinusitis, and accounts for approximately 11% of mortality worldwide in children under five years old (58) . S. pneumoniae can be classified into more than 90 capsular serotypes, and multivalent capsule polysaccharide (Pneumovax 23) and polysaccharide protein conjugate vaccines (PCV; 7 or 13-valent Prevnar, 10-valent Synflorix) (59) are currently available. However, many pneumococcal proteins are being evaluated for use in a universal serotype-independent vaccine, due to increasing antibiotic resistance and limitations of polysaccharide vaccines, including poor immunogenicity of unconjugated 8 vaccines in infants, the complexity and cost of PCVs, the variable regional distribution of serotypes and the restricted coverage of available vaccines (59), as well as the occurrence of serotype replacement after vaccination (60) .
The availability of multiple pneumococcal genome sequences combined with the increased understanding of pili in GBS and GAS led to the discovery of pili in S. pneumoniae and the investigation of pneumococcal pilus proteins as vaccine antigens (61, 62) . Pneumococcal pili are involved in adherence and virulence as well as stimulating the host inflammatory response (61) (62) (63) (64) .
Pilus 1 and pilus 2 are antigenically distinct and are encoded by two genomic pilus islets, PI-1 and PI-2, that are present in ~30% and 16% of pneumococcal clinical isolates, respectively (63, 65) . Pilus 1 is encoded by the rlrA islet, and is composed of three subunits, a backbone protein (RrgB) and two ancillary proteins (RrgA and RrgC) (55, 61, 62, 66) , while Pilus 2 consists of the backbone protein PitB Comparative genome analysis and subtractive Reverse Vaccinology, using the genomes of 2 NMEC, 5 UPEC strains, 1 pathogenic avian and 1 non-pathogenic E. coli K12 strain, led to the identification of 230 antigens present in ExPEC but absent (or poorly conserved) in non-pathogenic strains (5). This approach was aided by the earlier characterisation of outer membrane and secreted proteins by proteomic analysis of OMVs from pathogenic E. coli strains (70) (71) (72) . Further analysis of candidates led to the identification of nine potential vaccine antigens that, following immunization with the recombinant protein, were able to induce protection in a mouse challenge sepsis model. For the most protective antigen, ECOK1_3385, both active immunization with the recombinant protein, or passive immunization with sera raised against this antigen, provided nearly complete protection from bacteraemia and mortality in the mouse model of sepsis. ECOK1_3385 is widely distributed among E. coli pathotypes with amino acid sequence identity ranging from 86% to 100%. Some of the novel 9 protective antigens are also present in intestinal pathogenic E. coli, suggesting the possibility of a broadly protective vaccine against pathogenic E. coli (5).
Conclusions and Perspectives
Significant progress has been made in the field of vaccinology during the era of genomics, and vaccines are set to have an increasing impact on public health in the coming years. A decade of genome and proteome based Reverse Vaccinology, targeting bacterial pathogens including MenB, GBS, GAS, S. pneumoniae and pathogenic E. coli, has resulted in the discovery of numerous candidate vaccine antigens that are undergoing preclinical development, in addition to the clinical development of the 4CMenB vaccine (Figure 2 ). The continual advancements in genome sequencing technologies and the approaches used to screen the genome and proteome of a bacterial pathogen have greatly improved the efficiency and time needed for antigen discovery. These advancements have also improved antigen discovery and characterization for eukaryotic pathogens, which often encode more than 10,000 genes (73) . Genomics is also increasingly used to characterize variability between viral pathogens, which typically contain less than 10 genes (74).
Reverse vaccinology is now being applied to many bacterial, viral and eukaryotic pathogens and has been successful in all cases in providing novel antigens for the design of new vaccines (10) (11) (12) .
Furthermore, the ability to improve candidate antigens by rational design and structural vaccinology can provide increased protection against antigenically variable pathogens. For example, a structural vaccinology approach has been used to address the sequence variability of the MenB vaccine antigen fHbp, where a single antigen has been designed, which could elicit broadly protective immunity against strains expressing any fHbp variant, by grafting multiple immunodominant epitopes onto a single fHbp variant 1 molecule (75) . Similarly, a synthetic GBS pilus antigen has been constructed that comprises the protective domain of each of six variants of the backbone protein, BP-2a, to facilitate the development of a broadly protective pilus-based vaccine against GBS (76) . In addition, formulation of selected antigens with appropriate adjuvants may also expand the protection provided against variable pathogens. In the coming years, genomics will continue to contribute to vaccine development as human genomics and systems biology address questions aimed at understanding the types of immune responses needed to control certain diseases, the ways in which adjuvants direct the immune system and the different outcome of vaccination in the population. 36. Santolaya ME, O´Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al., editors.
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